Great News! Hemos has been awarded the 2025 China Bio-Manufacturing "Phoenix Award—Annual Industrialization Pioneer Award."

December 20–21, hosted by Arterial Network The “2025 China Bio-Manufacturing Industry Conference and Marine Bio-Manufacturing Exchange Meeting,” co-hosted by Dr. Fang, was successfully held in Sanya, Hainan.

This conference brings together a diverse array of key players—including founders of companies in the fields of bio-manufacturing and synthetic biology, seasoned investors, and experts from research institutions—aiming to facilitate efficient connections between industrial resources and innovative forces, while focusing on and recognizing the leading figures driving industry development.

At this conference, Hemos Bioscience stood out from numerous participating companies thanks to its outstanding performance in the industrialization of recombinant keratin technology, and successfully won the 2025 China Bio-Manufacturing “Phoenix Award—Annual Industrialization Pioneer Award.”

This award not only represents high recognition of the company’s strength in technological innovation, but also serves as an authoritative endorsement of its systematic capabilities in key areas such as engineering-scale-up, production cost control, product quality consistency, and green manufacturing. It highlights the company’s industry-leading ability to successfully translate technology into practical market value. 
 

This award further reinforces Hemos Bioscience’s development path of “innovation-driven, industry-based.” In the future, we will continue to deepen the iterative advancement of synthetic biology technologies, expand the application boundaries of recombinant keratin in high-value fields such as biomedicine and beauty & personal care, accelerate the industrialization of high-value consumables and medical devices, and refine our end-to-end industrial chain layout spanning “raw materials—applications—products.”

Hemos Bioscience will take technological innovation as its driving force, adopt a pioneering stance in industrialization, and promote the upgrading of bio-manufacturing toward scale, greenness, and commercialization, continuously injecting "Hemos power" into the high-quality development of China's bio-manufacturing.